New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:22 EDTALXNAlexion at an excellent entry point, says RW Baird
Baird is increasingly confident in Alexion's Solaris prospects both near and long-term. The firm also noted the company's robust pipeline and current valuation and remains buyers of the shares for a recovery into the $125 range. Shares are Outperform rated.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
06:31 EDTALXNAlexion announces $500M share repurchase program
Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.
December 12, 2014
08:01 EDTALXNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 10, 2014
16:20 EDTALXNAlexion reports Soliris granted orphan drug designation in Japan
Subscribe for More Information
December 9, 2014
05:33 EDTALXNAlexion presents Soliris data at ASH
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use